Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

Die Lesesäle für Geisteswissenschaften, Naturwissenschaften, der Alte Lesesaal Technik und der Anne-Frank-Shoah-Lesesaal in Leipzig schließen am 04.02.2026 wegen einer Veranstaltung bereits um 15 Uhr. Die weiteren Lesesäle sowie die Servicetheke sind zu den regulären Zeiten geöffnet. //
The humanities reading room, the natural science reading room, the old technology reading room and the reading room of the Anne-Frank-Shoah-Library will close at 15:00 on 4 February 2026 due to an event. The other reading rooms and the service desk will be open during regular hours.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

111 - 120 von 145

	111	Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials Enthalten in BioDrugs Bd. 34, 23.9.2020, Nr. 5, date:10.2020: 681-694
	112	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review Enthalten in BioDrugs Bd. 32, 22.5.2018, Nr. 3, date:6.2018: 193-199
	113	Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study Enthalten in Advances in rheumatology Bd. 65, 10.10.2025, Nr. 1, date:12.2025: 1-5
	114	Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study Enthalten in BioDrugs Bd. 35, 16.10.2021, Nr. 6, date:11.2021: 735-748
	115	Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin Enthalten in Diabetes therapy Bd. 13, 1.6.2022, Nr. 7, date:7.2022: 1299-1310
	116	Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin Enthalten in Diabetes therapy Bd. 12, 11.1.2021, Nr. 2, date:2.2021: 557-568
	117	Erythropoietin-induced Treatment Costs in Patients Suffering from Renal Anemia – A Comparison between Biosimilar and Originator Drugs Enthalten in Das Gesundheitswesen Bd. 76, 2014, Nr. 11: e79-e84
	118	Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial Enthalten in Scientific reports Bd. 14, 22.10.2024, Nr. 1, date:12.2024: 1-12
	119	Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis Enthalten in BMC health services research Bd. 19, 16.8.2019, Nr. 1, date:12.2019: 1-13
	120	Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database Enthalten in Journal of pharmaceutical health care and sciences Bd. 5, 7.10.2019, Nr. 1, date:12.2019: 1-4

111 - 120 von 145

Alle Materialarten

Alle Kataloge/Sammlungen

Alle Standorte > Leipzig (145)

Aktionen

Administration